27.54-0.19-0.69%
After-market 04:15:15 PM EDT 9/13/2024BTT
Plus500. 82% of retail CFD accounts lose money
27.73+0.18+0.64%
Official Close 03:59:59 PM EDT 9/13/2024BTT
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
Best Online Brokers for Stock TradingWant to trade stocks and other assets? Don't lose hundreds of dollars in avoidable transaction costs! Discover the best brokers for stock trading and ordering other assets!
On Friday 09/13/2024 the closing price of the Royalty Pharma share was $27.73 on BTT.Compared to the opening price on Friday 09/13/2024 on BTT of $27.97, this is a drop of 0.87%.Royalty Pharma's market capitalization is $10.57 B by 448.13 M shares outstanding.
Is Royalty Pharma stock a Buy, Sell or Hold?
Royalty Pharma stock has received a consensus rating of buy. The average rating score is and is based on 14 buy ratings, 1 hold ratings, and 0 sell ratings.What was the 52-week low for Royalty Pharma stock?
The low in the last 52 weeks of Royalty Pharma stock was 25.23. According to the current price, Royalty Pharma is 109.16% away from the 52-week low.What was the 52-week high for Royalty Pharma stock?
The high in the last 52 weeks of Royalty Pharma stock was 31.65. According to the current price, Royalty Pharma is 87.01% away from the 52-week high.What are analysts forecasts for Royalty Pharma stock?
The 15 analysts offering price forecasts for Royalty Pharma have a median target of 48.80, with a high estimate of 57.00 and a low estimate of 28.00. The median estimate represents a 56.43 difference from the last price of 27.54.Royalty Pharma Stock Snapshot
27.64
Bid
100.00
Bid Size
27.74
Ask
5.00
Ask Size
9/13/2024
Date
4:15 PM
Time
61,901.00
Volume
27.73
Prev. Close
27.70
Open
12.47 B
Market Cap in USD
448.13 M
Number of Shares
27.54
Day Low
27.81
Day High
27.54
25.23
52 Week Low
31.65
52 Week High
0.80
Dividend in USD
2.85
Dividend Yield
11.09
P/E Ratio
85.31
Free Float in %
2.54
EPS in USD
14.61
Book Value per Share in USD
5.03
Cash Flow per Share in USD
Royalty Pharma NewsMore News
RTTNews
Ascendis Pharma Reaches $150 Mln Royalty Funding Agreement With Royalty Pharma; Stock Drops
GlobeNewswire
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
GlobeNewswire
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
TipRanks
Buy Rating Affirmed for Royalty Pharma Amidst Strong Financials and Positive Growth Outlook
Historical Prices for Royalty Pharma
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Royalty Pharma Analyst Data
Total Analysts: 15
Buy Ratings: 14 Neutral Ratings: 1 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 28.00 Median: 48.80 Highest: 57.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Royalty Pharma Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 07/11/24 | Morgan Stanley | Maintained Buy | $51 | gut | ||
| 06/03/24 | UBS | Downgraded to Hold | $28 | neutral | ||
| 04/12/24 | Bank of America Merrill Lynch | Maintained Buy | $38 | gut | ||
| 02/20/24 | J.P. Morgan | Maintained Buy | $42 | gut | ||
| 02/20/24 | Goldman Sachs | Maintained Buy | $50 | gut | ||
| 11/09/23 | Morgan Stanley | Maintained Buy | $57 | gut | ||
| 10/11/23 | Morgan Stanley | Maintained Buy | $54 | gut | ||
| 08/09/23 | Morgan Stanley | Maintained Buy | $53 | gut | ||
| 07/11/23 | Morgan Stanley | Maintained Buy | $52 | gut | ||
| 05/10/23 | Morgan Stanley | Maintained Buy | $52 | gut | ||
| 04/10/23 | Morgan Stanley | Maintained Buy | $50 | gut | ||
| 02/16/23 | UBS | Maintained Buy | $48 | gut | ||
| 12/06/22 | Morgan Stanley | Maintained Buy | $51 | gut | ||
| 11/09/22 | Morgan Stanley | Maintained Buy | $54 | gut | ||
| 10/18/22 | J.P. Morgan | Maintained Buy | $52 | gut |
Royalty Pharma Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 2,684 | 2,957 | 3,316 | 3,904 | 4,441 |
| Dividend | 0.92 | 0.99 | 1.03 | - | - |
| Dividend Yield (in %) | 3.34 % | 3.59 % | 3.74 % | 4.40 % | - |
| EPS | 3.95 | 4.39 | 4.84 | 6.01 | 6.86 |
| P/E Ratio | 6.98 | 6.28 | 5.70 | 4.58 | 4.02 |
| EBIT | 2,500 | 2,321 | 2,648 | - | - |
| EBITDA | 2,537 | 2,779 | 3,032 | 3,584 | 4,081 |
| Net Profit | 2,346 | 2,594 | 2,840 | 3,484 | 3,981 |
| Net Profit Adjusted | 2,331 | 2,548 | 2,759 | 3,484 | 3,981 |
| Pre-Tax Profit | 1,999 | 2,160 | 2,486 | - | - |
| Pre-Tax Profit Reported | 2,402 | 2,479 | 2,752 | - | - |
| EPS (Non-GAAP) ex. SOE | 3.88 | 4.19 | 4.41 | - | - |
| EPS (GAAP) | 1.62 | 2.04 | - | - | - |
| Gross Income | - | - | - | - | - |
| Cash Flow from Investing | -2,070 | -1,987 | -1,987 | -1,474 | -1,474 |
| Cash Flow from Operations | 2,435 | 2,616 | 2,889 | 3,484 | 3,981 |
| Cash Flow from Financing | -172 | -556 | -490 | -1,216 | -1,209 |
| Cash Flow per Share | 4.37 | 4.65 | 5.23 | - | - |
| Free Cash Flow | 2,585 | 2,698 | 3,004 | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | 20.58 | 24.68 | 29.12 | - | - |
| Net Debt | 6,193 | 6,296 | 5,957 | - | - |
| Research & Development Exp. | - | - | - | - | - |
| Capital Expenditure | 0 | 0 | 0 | - | - |
| Selling, General & Admin. Exp. | 230 | 251 | 268 | - | - |
| Shareholder’s Equity | 12,024 | 14,151 | 15,787 | 18,163 | 19,911 |
| Total Assets | 19,693 | 21,543 | 23,230 | 23,160 | 24,507 |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 6 | 6 | 7 | 7 |
| Average Estimate | - | 0.919 USD | 1.083 USD | 3.949 USD | 4.390 USD |
| Year Ago | - | 0.161 USD | 1.106 USD | 2.535 USD | - |
| Publish Date | - | 11/6/2024 | 2/12/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 5 | 5 | 7 | 7 |
| Average Estimate | - | 694 USD | 695 USD | 2,684 USD | 2,957 USD |
| Year Ago | - | 536 USD | 596 USD | 2,355 USD | - |
| Publish Date | - | 11/6/2024 | 2/12/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 2,354.55 | 2,237.22 | 2,289.46 | 2,122.35 | 1,814.25 | 1,794.89 | 1,597.93 |
| Change of sales in % | 5.24 | -2.28 | 7.87 | 16.98 | 1.08 | 12.33 | -14.89 |
| Gross profit on sales | - | 2,231.55 | 2,266.47 | - | - | - | 1,564.66 |
| Gross profit on sales change in % | - | -1.54 | - | - | - | - | - |
| Operating income | 1,492.15 | 922.89 | 1,430.72 | 1,595.40 | 2,623.18 | 1,364.45 | 939.69 |
| Operating income change in % | 61.68 | -35.49 | -10.32 | -39.18 | 92.25 | 45.20 | 29.99 |
| Income before tax | 1,700.09 | 230.06 | 1,241.20 | 1,701.95 | 2,461.42 | 1,517.86 | 1,343.18 |
| Income before tax change in % | 638.96 | -81.46 | -27.07 | -30.85 | 62.16 | 13.00 | 76.29 |
| Income after tax | 1,134.83 | 42.83 | 619.73 | 975.04 | 2,348.54 | 1,377.73 | 1,210.03 |
| Income after tax change in % | 2,549.50 | -93.09 | -36.44 | -58.48 | 70.46 | 13.86 | 113.82 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 6,297.56 | 7,288.09 | 7,267.32 | 6,124.47 | 6,308.46 | 6,818.07 | 6,904.27 |
| Long-term liabilities per share | 13.74 | 13.81 | 16.39 | 14.99 | 16.33 | 10.28 | 10.74 |
| Equity | 10,084.29 | 9,525.37 | 10,248.55 | 9,895.82 | 6,141.44 | 4,552.08 | 4,460.55 |
| Equity change in % | 15.96 | -2.57 | 19.88 | -21.08 | 36.04 | 0.62 | 0.34 |
| Balance sheet total | 16,381.85 | 16,813.47 | 17,515.87 | 16,020.29 | 12,449.90 | 11,370.15 | 11,364.81 |
| Balance sheet total change in % | -2.57 | -4.01 | 9.34 | 28.68 | 9.50 | 0.05 | 8.57 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 3.91 | 5.11 | 5.52 | 5.65 | 4.96 | 2.96 | 2.63 |
| P/E ratio (year end quote, basic EPS) | 11.09 | 404.09 | 26.67 | 19.27 | - | - | - |
| P/E ratio (year end quote, diluted EPS) | 11.09 | 404.09 | 26.67 | 19.27 | - | - | - |
| P/E ratio (year end quote) | 11.09 | 404.09 | 26.67 | 19.27 | - | - | - |
| Dividend yield in % | 2.85 | 1.92 | 1.71 | 0.60 | - | - | - |
| Equity ratio in % | 39.84 | 33.47 | 32.98 | 30.08 | 49.04 | 39.47 | 39.22 |
| Debt ratio in % | 38.44 | 43.35 | 41.49 | 38.23 | 50.67 | 59.96 | 60.70 |
Royalty Pharma Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Fernandez Henry A | 06/27/2024 | 1,399.00 | 52,660.00 | 26.80 | Buy | No |
| Bassler Bonnie L | 06/27/2024 | 1,399.00 | 58,454.00 | 26.80 | Buy | No |
| Norden Gregory | 06/06/2024 | 9,293.00 | 73,738.00 | n/a | Buy | No |
| Bassler Bonnie L | 06/06/2024 | 9,293.00 | 57,055.00 | n/a | Buy | No |
| Fernandez Henry A | 06/06/2024 | 9,293.00 | 51,261.00 | n/a | Buy | No |
| Engelbert Catherine M. | 06/06/2024 | 9,293.00 | 43,514.00 | n/a | Buy | No |
| DESOUZA ERROL B | 06/06/2024 | 9,293.00 | 73,738.00 | n/a | Buy | No |
| Hite Christopher | 05/12/2024 | 300,000.00 | 370,000.00 | n/a | Buy | No |
| Bassler Bonnie L | 03/27/2024 | 1,240.00 | 47,762.00 | 30.23 | Buy | No |
| RIGGS RORY B | 02/19/2024 | 300,000.00 | 320,099.00 | n/a | Buy | No |
| Giuliani Mario Germano | 12/28/2023 | 65,803.00 | 2,477,520.00 | 28.04 | Sell | No |
| Fernandez Henry A | 12/28/2023 | 1,353.00 | 40,728.00 | 27.71 | Buy | No |
| Bassler Bonnie L | 12/28/2023 | 1,353.00 | 46,522.00 | 27.71 | Buy | No |
| Giuliani Mario Germano | 12/27/2023 | 209,863.00 | 2,543,323.00 | 28.20 | Sell | No |
| Giuliani Mario Germano | 12/26/2023 | 41,729.00 | 2,753,186.00 | 28.01 | Sell | No |
| Giuliani Mario Germano | 12/14/2023 | 10,229.00 | 2,794,915.00 | 28.01 | Sell | No |
| Giuliani Mario Germano | 12/13/2023 | 364,441.00 | 2,805,144.00 | 28.91 | Sell | No |
| Giuliani Mario Germano | 12/12/2023 | 307,935.00 | 3,169,585.00 | 28.95 | Sell | No |
| RIGGS RORY B | 11/12/2023 | 475,590.00 | 490,099.00 | n/a | Buy | No |
| Bassler Bonnie L | 09/28/2023 | 1,384.00 | 45,169.00 | 27.08 | Buy | No |
| Fernandez Henry A | 09/28/2023 | 1,384.00 | 39,375.00 | 27.08 | Buy | No |
| Coyne Terrance P. | 08/09/2023 | 37,500.00 | 790,000.00 | 30.75 | Sell | No |
| Coyne Terrance P. | 08/08/2023 | 37,500.00 | 827,500.00 | 30.72 | Sell | No |
| Coyne Terrance P. | 07/12/2023 | 37,500.00 | 865,000.00 | 30.93 | Sell | No |
| Coyne Terrance P. | 07/11/2023 | 37,500.00 | 902,500.00 | 31.07 | Sell | No |
Royalty Pharma Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Royalty Pharma | 0.80 | 2.85 | USD |
| 2022 | Royalty Pharma | 0.76 | 1.92 | USD |
| 2021 | Royalty Pharma | 0.68 | 1.71 | USD |
| 2020 | Royalty Pharma | 0.30 | 0.60 | USD |
| 2019 | Royalty Pharma | - | - | USD |
| 2018 | Royalty Pharma | - | - | USD |
| 2017 | Royalty Pharma | - | - | USD |
| 2016 | Royalty Pharma | - | - | USD |
| 2015 | Royalty Pharma | - | - | USD |
*Yield of the Respective Date
Royalty Pharma Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 0.919 USD | Q3 2024 Earnings Release | 11/06/2024 |
| Earnings Report | 1.083 USD | Q4 2024 Earnings Release | 02/12/2025 |
| Earnings Report | 1.100 USD | Q1 2025 Earnings Release | 05/07/2025 |
| Earnings Report | 1.120 USD | Q2 2025 Earnings Release | 08/06/2025 |
Royalty Pharma Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 0.226 USD | Q2 2024 Earnings Release | 08/08/2024 |
Royalty Pharma Profile
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
6
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Royalty Pharma Shareholder
| Owner | in % |
|---|---|
| Freefloat | 85.31 |
| Nogra Group SICAF-SIF SA | 9.29 |
| Morgan Stanley Investment Management, Inc. | 8.84 |
| The Vanguard Group, Inc. | 8.48 |
| Vanguard Group, Inc. (Subfiler) | 8.25 |
| Morgan Stanley Investment Management, Inc. | 8.10 |
| Fidelity Management & Research Co. LLC | 4.67 |
| Baillie Gifford & Co. | 3.65 |
| Vanguard Total Stock Market ETF | 2.71 |
| Viking Global Investors LP | 2.67 |
| Adage Capital Partners GP LLC | 2.44 |
| Swedbank AB | 2.41 |
| Mario Germano Giuliani, PhD | 2.31 |
| BlackRock Institutional Trust Co. NA | 2.17 |
| State Street Corp. | 2.12 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
